13F Data
13F filer · CIK 1281446

GREAT POINT PARTNERS LLC

Greenwich, CT · filing since Q3 2013 · last filing Aug 14, 2026
Reported value
$529.1M
+$94.0M vs prior
Positions
42
New / sold out
13 / 13
Added / reduced
7 / 9
Turnover
36.8%
buys $220.5M · sells $177.6M
Top-10 weight
51.6%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewABIVAX SACALL+400,000–+$53.3M
NewABIVAX SA+204,314–+$27.2M
NewULTRAGENYX PHARMACEUTICAL INPUT+600,000–+$20.0M
NewDEFINIUM THERAPEUTICS INC+425,000–+$20.0M
AddedVERA THERAPEUTICS INC+401,488+201.4%+$17.2M
NewSAGIMET BIOSCIENCES INC+2,029,933–+$15.7M
AddedIMMIX BIOPHARMA INC+927,642+265.0%+$9.6M
AddedMOONLAKE IMMUNOTHERAPEUTICS+355,813+71.2%+$6.9M
NewINFLARX NV+3,046,557–+$6.8M
AddedOPUS GENETICS INC+1,645,847+507.4%+$6.8M
10 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outAPOGEE THERAPEUTICS INC-374,000-100.0%$-31.5M
ReducedAMYLYX PHARMACEUTICALS INC-1,050,000-60.0%$-18.9M
Sold outKALVISTA PHARMACEUTICALS INC-675,000-100.0%$-13.6M
Sold outIMMUNOVANT INC-545,625-100.0%$-13.6M
Sold outJADE BIOSCIENCES INC-964,462-100.0%$-13.6M
Sold outZENAS BIOPHARMA INC-524,066-100.0%$-10.2M
ReducedNEKTAR THERAPEUTICS-141,453-44.7%$-9.9M
ReducedBRIGHT MINDS BIOSCIENCES INC-110,397-50.2%$-7.7M
Sold outCOMPASS THERAPEUTICS INC-1,350,000-100.0%$-7.1M
Sold outSCYNEXIS INC-7,554,347-100.0%$-6.9M
12 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q3 2013: $144.1MQ4 2013: $141.6MQ1 2014: $191.5MQ2 2014: $224.8MQ3 2014: $232.8MQ4 2014: $207.8MQ1 2015: $227.2MQ2 2015: $256.5MQ3 2015: $252.8MQ4 2015: $238.3MQ1 2016: $278.7MQ2 2016: $349.2MQ3 2016: $392.1MQ4 2016: $486.8MQ1 2017: $503.5MQ2 2017: $558.2MQ3 2017: $514.0MQ4 2017: $586.1MQ1 2018: $673.4MQ2 2018: $721.6MQ3 2018: $641.7MQ4 2018: $791.2MQ1 2019: $1.0BQ2 2019: $900.8MQ3 2019: $1.1BQ4 2019: $1.1BQ1 2020: $957.1MQ2 2020: $1.3BQ3 2020: $1.1BQ4 2020: $615.7MQ1 2021: $483.9MQ2 2021: $476.7MQ3 2021: $429.5MQ4 2021: $450.1MQ1 2022: $413.8MQ2 2022: $417.0MQ3 2022: $415.3MQ4 2022: $510.2MQ1 2023: $509.3MQ2 2023: $510.8MQ3 2023: $549.0MQ4 2023: $586.7MQ1 2024: $641.6MQ2 2024: $522.0MQ3 2024: $339.8MQ4 2024: $212.2MQ1 2025: $188.8MQ2 2025: $153.8MQ3 2025: $242.5MQ4 2025: $308.4MQ1 2026: $435.1MQ2 2026: $529.1M
Q3 2013Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1ABIVAX SACALLSPONSORED ADS400,000$53.3M10.07%
2VOR BIOPHARMA INCCOM NEW1,700,000$31.3M5.91%
3ABIVAX SASPONSORED ADS204,314$27.2M5.15%
4IMMUNITYBIO INCPUTCOM3,000,800$26.3M4.97%
5VERA THERAPEUTICS INCCL A600,836$25.8M4.87%
6ZURA BIO LTDCLASS A ORD SHS4,215,930$24.9M4.70%
7ALUMIS INCCOM856,061$24.1M4.55%
8SOL-GEL TECHNOLOGIES LTDSHS NEW274,363$20.3M3.84%
9ULTRAGENYX PHARMACEUTICAL INPUTCOM600,000$20.0M3.79%
10DEFINIUM THERAPEUTICS INCCOM SHS425,000$20.0M3.78%
32 more rows. Subscribe for $29/month to see every row, download the data and use the API.